NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September
NewAmsterdam Pharma (NASDAQ: NAMS), a late-stage biopharma company focused on developing oral, non-statin medicines for cardiovascular disease patients, has announced its participation in multiple scientific and investor events in September 2025.
The company will present pooled safety and efficacy data from its Phase 3 BROADWAY and BROOKLYN trials for obicetrapib at the European Society of Cardiology Congress in Madrid. Additionally, management will participate in three investor conferences: Citi's Biopharma Back to School Summit, Cantor Global Healthcare Conference, and Wells Fargo Healthcare Conference.
[]NewAmsterdam Pharma (NASDAQ: NAMS), una società biofarmaceutica in fase avanzata focalizzata sullo sviluppo di farmaci orali non a base di statine per pazienti con malattie cardiovascolari, ha annunciato la sua partecipazione a diversi eventi scientifici e per investitori a settembre 2025.
La società presenterà i dati aggregati di sicurezza ed efficacia dei suoi trial di Fase 3 BROADWAY e BROOKLYN su obicetrapib al Congresso della Società Europea di Cardiologia a Madrid. Inoltre, il management parteciperà a tre conferenze per investitori: il Biopharma Back to School Summit di Citi, il Cantor Global Healthcare Conference e il Wells Fargo Healthcare Conference.
NewAmsterdam Pharma (NASDAQ: NAMS), una compañía biofarmacéutica en fase avanzada centrada en desarrollar medicamentos orales no estatinas para pacientes con enfermedades cardiovasculares, ha anunciado su participación en varios eventos científicos y para inversores en septiembre de 2025.
La empresa presentará los datos combinados de seguridad y eficacia de sus ensayos de Fase 3 BROADWAY y BROOKLYN sobre obicetrapib en el Congreso de la Sociedad Europea de Cardiología en Madrid. Además, la dirección participará en tres conferencias para inversores: el Biopharma Back to School Summit de Citi, el Cantor Global Healthcare Conference y el Wells Fargo Healthcare Conference.
NewAmsterdam Pharma (NASDAQ: NAMS)는 심혈관 질환 환자를 위한 경구용 비스타틴 약물 개발에 주력하는 후기 단계 바이오제약사로, 2025년 9월 여러 학술 및 투자자 행사에 참여한다고 발표했습니다.
회사는 마드리드에서 열리는 유럽심장학회(ESC) 총회에서 오비세트라픽(obicetrapib)에 대한 제3상 BROADWAY 및 BROOKLYN 임상시험의 안전성 및 유효성 종합 데이터를 발표할 예정입니다. 또한 경영진은 Citi의 Biopharma Back to School Summit, Cantor Global Healthcare Conference, Wells Fargo Healthcare Conference 등 세 건의 투자자 콘퍼런스에 참가할 예정입니다.
NewAmsterdam Pharma (NASDAQ: NAMS), une société biopharmaceutique en phase avancée spécialisée dans le développement de médicaments oraux non statines pour les patients atteints de maladies cardiovasculaires, a annoncé sa participation à plusieurs événements scientifiques et pour investisseurs en septembre 2025.
La société présentera au Congrès de la Société Européenne de Cardiologie à Madrid les données compilées de sécurité et d’efficacité issues de ses essais de phase 3 BROADWAY et BROOKLYN sur l'obicetrapib. De plus, la direction participera à trois conférences pour investisseurs : le Biopharma Back to School Summit de Citi, le Cantor Global Healthcare Conference et le Wells Fargo Healthcare Conference.
NewAmsterdam Pharma (NASDAQ: NAMS), ein Biopharmaunternehmen in der Spätphase, das oral anwendbare, nicht-statinhaltige Medikamente für Patienten mit Herz-Kreislauf-Erkrankungen entwickelt, hat seine Teilnahme an mehreren wissenschaftlichen und Investorenveranstaltungen im September 2025 angekündigt.
Das Unternehmen wird beim Kongress der European Society of Cardiology in Madrid gepoolte Sicherheits- und Wirksamkeitsdaten aus seinen Phase-3-Studien BROADWAY und BROOKLYN zu Obicetrapib vorstellen. Darüber hinaus wird das Management an drei Investorenkonferenzen teilnehmen: dem Biopharma Back to School Summit von Citi, der Cantor Global Healthcare Conference und der Wells Fargo Healthcare Conference.
- None.
- None.
NAARDEN, The Netherlands and MIAMI, Aug. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present additional pooled safety and efficacy data from the pivotal Phase 3 BROADWAY and BROOKLYN trials at the European Society of Cardiology Congress (ESC), taking place August 29 – September 1, 2025 in Madrid, Spain. Additionally, NewAmsterdam announced that company management will participate in three upcoming investor conferences. Details are as follows:
European Society of Cardiology Congress (ESC) 2025
Presentation Title: Efficacy of obicetrapib across the spectrum of background lipid lowering therapies-pooled analyses of the Broadway and Brooklyn randomized trials
Session Title: Changing face of lipid-lowering therapy
Presentation Date and Time: Friday, August 29, 2025 at 10:10am CEST
Presenter: Kausik Ray, M.D.
Presentation Title: Obicetrapib and cardiovascular events
Session Title: Late-Breaking Clinical Science: lipids and cardiovascular risk
Presentation Date and Time: Monday, September 1, 2025 at 9:00am CEST
Presenter: Stephen Nicholls, M.D.
Citi’s 2025 Biopharma Back to School Summit
Fireside Chat Date and Time: Wednesday, September 3, 2025 at 2:30pm ET in Boston, MA
Presenters: Michael Davidson, M.D., Chief Executive Officer, and Ian Somaiya, Chief Financial Officer
Cantor Global Healthcare Conference 2025
Fireside Chat Date and Time: Thursday, September 4, 2025 at 2:45pm ET in New York, NY
Presenters: Michael Davidson, M.D., Chief Executive Officer, and Ian Somaiya, Chief Financial Officer
Wells Fargo Healthcare Conference
Fireside Chat Date and Time: Friday, September 5, 2025 at 10:15am ET in Boston, MA
Presenter: Ian Somaiya, Chief Financial Officer
Live webcasts of the fireside chat presentations will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcasts, archived replays will be available on the Company’s website.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
Media Contact
Real Chemistry on behalf of NewAmsterdam
Christian Edgington
P: 1-513-310-6410
cedgington@realchemistry.com
Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com
FAQ
When will NewAmsterdam Pharma (NAMS) present its Phase 3 trial data at ESC 2025?
Which investor conferences will NewAmsterdam Pharma (NAMS) attend in September 2025?
How can investors access NewAmsterdam Pharma's (NAMS) conference presentations?
What clinical trial data will NewAmsterdam Pharma (NAMS) present at ESC 2025?
